Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78
July 4, 2012
Alain Schwenck, an Expert on Pharmaceutical Prodcution, becomes Director of Genethon Bioprod
Alain Schwenck, 51, has joined Genethon as Director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon.
(read more)January 17, 2012
Fulvio Mavilio, the internationally acknowledged expert in gene therapy for rare diseases, is appointed as Genethon’s new Scientific Director
Fulvio Mavilio, PhD is appointed as the new Scientific Director of Généthon.
(read more)January 12, 2012
Gene therapy : Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C
The results of a Phase I clinical trial of gene therapy for limb-girdle muscular dystrophy type 2C (a rare neuromuscular disease) have just been published in the journal Brain on January 11, 2012.
(read more)July 21, 2011
Genethon and Children’s Hospital Boston get FDA approval for a Wiskott Aldrich gene therapy trial
The US Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS).
(read more)March 8, 2011
Genethon and Wake Forest University School of Medicine (North Carolina) announce their collaboration for a preclinical gene therapy trial
Evry (France), March 8th, 2011 – Genethon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (Association Française contre les Myopathies, AFM) with donations from France’s annual Telethon) and Wake Forest University School of Medicine (Winston Salem, North Carolina, USA)… (read more)
January 5, 2011
Partnership for a gene therapy Clinical trial signed between Genethon and Children’s Hospital Boston
A unique multicenter international study of gene therapy for a rare genetic disease (Wiskott-Aldrich syndrome) led in London, Paris and Boston.
(read more)December 14, 2010
bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy
This agreement is designed to enable substantial advances in existing manufacturing process for the benefit of both partners.
(read more)June 3, 2010
Innovative biotherapies and genetic eye diseases
Innovative biotherapies and genetic eye diseases: the Réseau Thérapie Génique Oculaire (Ocular Gene Therapy Network) prepares to launch human trials
(read more)February 24, 2010
Généthon initiates a new clinical trial for a severe immune deficiency (Wiskott-Aldrich syndrome)
Généthon, the not-for-profit biotherapy laboratory operated by the French Muscular Dystrophy Association (AFM) with funding from the country’s annual Telethon*, has just obtained approval from the French and British health authorities for a Phase I/II clinical trial of gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome… (read more)
February 23, 2010
Genethon appoints biopharma industry expert Frédéric Revah as Chief Executive
Genethon, the not-for-profit biotherapy research centre created by the French Muscular Dystrophy Association (AFM) and funded with donations from the country’s annual Telethon, today announced the appointment of Frédéric Revah PhD as Chief Executive.
(read more)February 15, 2010
An effective gene therapy approach for dysferlin deficiencies
Research scientists at Généthon find a solution to the problem of the dysferlin gene’s size to transport it into muscle.
(read more)June 16, 2009
Thermo Fischer Scientific 2009 prize
Anne Galy, winner of the Biotherapy prize for her project “gene therapy in Wiskott-Aldrich syndrome”
(read more)February 20, 2009
Gene therapy: Production of the first batch of HIV-derived vectors in Europe for use in a human clinical trial
Genethon, the laboratory created and funded by the AFM (French Association against Myopathies) using donations from Téléthon, today announced that it has produced, controlled and released a batch of lentiviral vectors derived from the human immunodeficiency (HIV) virus for a gene therapy trial in humans in a rare immune deficiency. The… (read more)
February 12, 2008
Neuromuscular diseases: A pharmacological therapeutic approach for certain sarcoglycanopathies
A research team led by Dr Isabelle Richard (CNRS-FRE3087) from the Genethon laboratory financed by the AFM through Téléthon donations has just demonstrated the efficacy of a novel pharmacological strategy in the mouse for certain mutations of alpha-sarcoglycanopathy or LGMD2D, a recessive limb girdle dystrophy. This pharmacological strategy… (read more)
